<p>ArriVent BioPharma（纳斯达克股票代码：AVBP）周三公布了季度财报数据。公司报告称，本季度每股收益（EPS）为（$0.65），与市场预期的（$0.65）相符，据 Zacks 报道。</p>
<p>获取 <strong>ArriVent BioPharma</strong> 的警报：</p>
<h2>ArriVent BioPharma 股价下跌 0.4%</h2>
<p>AVBP 周四下跌$0.09，报$23.86。公司交易量为 110,115 股，低于平均交易量 122,485 股。ArriVent BioPharma 过去 12 个月的最低价为$14.35，最高价为$25.95。公司 50 天移动平均价为$19.57，200 天移动平均价为$19.16。</p>
<h2>分析师升级和降级</h2>
<p>AVBP 成为多份分析师报告的研究对象。Oppenheimer 重申对 ArriVent BioPharma 的 “表现优异” 评级，并在周四的一份报告中发布了$35.00 的目标股价。HC Wainwright 在 6 月 6 日周四的一份报告中重申了 “买入” 评级，并发布了$25.00 的目标股价。根据 MarketBeat.com 的数据，五位分析师对该股票给予买入评级，目前市场普遍评级为 “买入”，平均目标股价为$30.40。</p>
<p><strong>查看我们对 ArriVent BioPharma 的最新股票报告</strong></p>
<h2>ArriVent BioPharma 公司简介（获取免费报告）</h2>
<p>ArriVent BioPharma，Inc 是一家在美国从事为患有癌症患者提供未满足医疗需求的药物的识别、开发和商业化的临床阶段生物制药公司。公司还致力于开发和商业化针对非小细胞肺癌（NSCLC）和其他实体肿瘤的靶向癌症疗法。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们比 ArriVent BioPharma 更喜欢的股票</li>
<li>投资者如何找到最好的便宜股息股票</li>
<li>Michael Burry 的阿里巴巴赌注及更广泛的市场影响</li>
<li>如何使用 MarketBeat Excel 股息计算器</li>
<li>Jeff Brown 的 Exegesis AI 股票推荐</li>
<li>交易量异常的股票：如何实时找到异常交易量股票</li>
<li>沃伦·巴菲特的赌注：为什么伯克希尔哈撒韦买入了 Ulta 股票</li>
</ul>
<p><em>此即时新闻警报由 Narrative Science 技术和 MarketBeat 的财务数据生成，以向读者提供最快速和最准确的报道。本故事在发布前经 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ 您的 iPhone 意外之财？（来自 InvestorPlace）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTc4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTc4"/></p>
<h2>您现在是否应该投资$1,000 在 ArriVent BioPharma？</h2>
<p>在考虑投资 ArriVent BioPharma 之前，您需要听到这个。</p>
<p>MarketBeat 每天跟踪华尔街顶尖和表现最佳的研究分析师以及他们向客户推荐的股票。MarketBeat 已确定了五只顶级分析师悄悄告诉客户现在购买的股票...而 ArriVent BioPharma 不在名单上。</p>
<p>虽然 ArriVent BioPharma 目前在分析师中有 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

纳斯达克综合指数

纳斯达克 100 科技市值加权指数

AVBP

<p>阿睿飞生物制药（NASDAQ:AVBP）宣布其季度盈利结果，报告每股收益符合分析师的预期。尽管如此，股价下跌了 0.4%，交易价为 0.86 美元。分析师们重申了公司的目标价格，Oppenheimer 和 HC Wainwright 均发出买入评级。目前股票的共识评级为 “买入”，平均目标价为 1.40 美元。阿睿飞专注于开发针对癌症的靶向疗法，特别是非小细胞肺癌</p>

<p>ArriVent BioPharma (NASDAQ:AVBP - Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.65) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.65), Zacks reports.</p>
<div class="lb-trans"><p>ArriVent BioPharma（纳斯达克股票代码：AVBP）周三公布了季度财报数据。公司报告称，本季度每股收益（EPS）为（$0.65），与市场预期的（$0.65）相符，据 Zacks 报道。</p>
</div><p>Get <strong>ArriVent BioPharma</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>ArriVent BioPharma</strong> 的警报：</p>
</div><h2>ArriVent BioPharma Stock Down 0.4 %</h2>
<div class="lb-trans"><h2>ArriVent BioPharma 股价下跌 0.4%</h2>
</div><p>AVBP traded down $0.09 on Thursday, hitting $23.86. 110,115 shares of the company traded hands, compared to its average volume of 122,485. ArriVent BioPharma has a 12-month low of $14.35 and a 12-month high of $25.95. The company has a 50 day moving average of $19.57 and a 200-day moving average of $19.16.</p>
<div class="lb-trans"><p>AVBP 周四下跌$0.09，报$23.86。公司交易量为 110,115 股，低于平均交易量 122,485 股。ArriVent BioPharma 过去 12 个月的最低价为$14.35，最高价为$25.95。公司 50 天移动平均价为$19.57，200 天移动平均价为$19.16。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师升级和降级</h2>
</div><p>AVBP has been the topic of several analyst reports. Oppenheimer reaffirmed an &#34;outperform&#34; rating and issued a $35.00 target price on shares of ArriVent BioPharma in a report on Thursday. HC Wainwright reissued a &#34;buy&#34; rating and issued a $25.00 target price on shares of ArriVent BioPharma in a report on Thursday, June 6th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of &#34;Buy&#34; and an average price target of $30.40.</p>
<div class="lb-trans"><p>AVBP 成为多份分析师报告的研究对象。Oppenheimer 重申对 ArriVent BioPharma 的 “表现优异” 评级，并在周四的一份报告中发布了$35.00 的目标股价。HC Wainwright 在 6 月 6 日周四的一份报告中重申了 “买入” 评级，并发布了$25.00 的目标股价。根据 MarketBeat.com 的数据，五位分析师对该股票给予买入评级，目前市场普遍评级为 “买入”，平均目标股价为$30.40。</p>
</div><p><strong>Check Out Our Latest Stock Report on ArriVent BioPharma</strong></p>
<div class="lb-trans"><p><strong>查看我们对 ArriVent BioPharma 的最新股票报告</strong></p>
</div><h2>ArriVent BioPharma Company Profile (Get Free Report)</h2>
<div class="lb-trans"><h2>ArriVent BioPharma 公司简介（获取免费报告）</h2>
</div><p>ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.</p>
<div class="lb-trans"><p>ArriVent BioPharma，Inc 是一家在美国从事为患有癌症患者提供未满足医疗需求的药物的识别、开发和商业化的临床阶段生物制药公司。公司还致力于开发和商业化针对非小细胞肺癌（NSCLC）和其他实体肿瘤的靶向癌症疗法。</p>
</div><h2>Recommended Stories</h2>
<ul>
<li>Five stocks we like better than ArriVent BioPharma</li>
<li>How Investors Can Find the Best Cheap Dividend Stocks</li>
<li>Michael Burry's Alibaba Bet and the Broader Market Implications</li>
<li>How to Use the MarketBeat Excel Dividend Calculator</li>
<li>Jeff Brown's Exegesis AI Stock Picks</li>
<li>Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time</li>
<li>Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock</li>
</ul>
<div class="lb-trans"><h2>推荐故事</h2>
<ul>
<li>五只我们比 ArriVent BioPharma 更喜欢的股票</li>
<li>投资者如何找到最好的便宜股息股票</li>
<li>Michael Burry 的阿里巴巴赌注及更广泛的市场影响</li>
<li>如何使用 MarketBeat Excel 股息计算器</li>
<li>Jeff Brown 的 Exegesis AI 股票推荐</li>
<li>交易量异常的股票：如何实时找到异常交易量股票</li>
<li>沃伦·巴菲特的赌注：为什么伯克希尔哈撒韦买入了 Ulta 股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由 Narrative Science 技术和 MarketBeat 的财务数据生成，以向读者提供最快速和最准确的报道。本故事在发布前经 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ Your iPhone windfall? (From InvestorPlace)(Ad)</p>
<div class="lb-trans"><p>→ 您的 iPhone 意外之财？（来自 InvestorPlace）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTc4" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9178&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in ArriVent BioPharma right now?</h2>
<div class="lb-trans"><h2>您现在是否应该投资$1,000 在 ArriVent BioPharma？</h2>
</div><p>Before you consider ArriVent BioPharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 ArriVent BioPharma 之前，您需要听到这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ArriVent BioPharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶尖和表现最佳的研究分析师以及他们向客户推荐的股票。MarketBeat 已确定了五只顶级分析师悄悄告诉客户现在购买的股票...而 ArriVent BioPharma 不在名单上。</p>
</div><p>While ArriVent BioPharma currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 ArriVent BioPharma 目前在分析师中有 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

ArriVent BioPharma（纳斯达克：AVBP）公布收益结果